Loading...
Loading...
In a report published Wednesday, Canaccord Genuity reiterated its Buy rating and $11.00 price target on Raptor Pharmaceutical
RPTP.
Canaccord Genuity noted, “Reiterate BUY, $11 target on high chance of PROCYSBI H1/13 US and 2014 EU approval/launch. We expect PROCYSBI to be approved in the US (March 30 PDUFA) and EU, with H1/13 and 2014 launches, respectively. We predict manageable payor pushback on premium orphan pricing and quick adoption. Our $11 target is based on a pNPV analysis.”
Raptor Pharmaceutical closed on Monday at $5.39.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in